Dr Xiang-Qun (Sean) Xie is an Associate Dean for Research Innovation at School of Pharmacy and a Professor of Pharmaceutical Sciences/Drug Discovery Institute, and a PI of an integrated Medicinal Chemistry Biology laboratory of CompuGroup, BioGroup and ChemGroup (www.CBLigand.org/XieLab) at University of Pittsburgh. He is a member of the Science Advisory Board to the US FDA. He is a Founding Director of Computational Chemical Genomics Screening Center (www.CBLigand.org/CCGS), and a Director/PI of NIH National Center of Excellence for CDAR (www.CDARCenter.org). He holds joint positions at Dept of Computational Biology and Dept of Structural Biology, and Pitt Cancer Institute MT/DD Program. He is an Editorial Advisory Board member for AAPS Journal and American Journal of Molecular Biology, and Associate Editor of BMC Pharmacology Toxicology. He was a Charter Member of NIH BPNS Study Section, and an ad hoc expert reviewer for UK MRC foundation; the Wellcome Trust Fund; the Netherland Organization for Scientific Research Council; the Austrian Science Fund (FWF) Erwin Schrödinger Fellowship; and the Chinese Natural Science Foundation. He holds/held honorary professorship in top institutes and colleges of pharmacy in China, including Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Stem Cell Medical Center; and Shanghai Jiaotong University. He was an invited International Assessment Panelist for Fudan University, a member of the Board of Directors of the Chinese Association of Professionals in Science and Technology, and a Chair of the CAPST-Biomedical & Pharmaceutical Society.
Prof Xie and his team are known for their pioneering research for the development of internationally recognized diseases domain-specific chemogenomics knowledgebases, which is an integrated platform of “Big Data to Knowledge” computational chemogenomics-based target identification and system pharmacology for translational research. His recent work on Alzheimer’s disease specific chemogenomics database (www.CBLigand.org/AD/) was on 2014 coverpage story of a top peer-reviewed ACS journal. The innovation work includes GPU-accelerated cloud computing TargetHunter program for drug target identification (www.CBLigand.org/TargetHunter) (2013 AAPS special theme issue). His lab was the first discovered/patented INK4C-targeting small molecule inhibitors for hematopoietic stem cell expansion (Nature Comm 2015), was the first discovered/patented p62ZZ chemical inhibitors for multiple myeloma (Nature Leukemia 2015), and also reported/patented novel ligands specific to cannabinoid CB2 receptor for osteoporosis and cancers. His invention discovery patents have been successfully licensed out to Biotech/Pharma. Overall, his developed integrated cloud computing knowledgebases help to bridge the knowledge gap between biology and chemistry, and to facilitate target identification, drug repurposing, and system pharmacology analyses in a chemogenomics scale for precision medicine drug discovery. As a result, he is a recipient of 2014 AAPS Award for Outstanding Research Achievements.
Dr Xie received MD in Pharmacy from the Second Military Medical University in Shanghai China, PhD in Medicinal Chemistry from the School of Pharmacy, University of Connecticut, and Executive MBA degree, and the Shared Leadership Cohort Development Experience Workshop Training by JPorcari & Associates.